Myasthenia Gravis Treatment Market Size - Global Industry, Share, Analysis, Trends and Forecast 2023 - 2032
CHAPTER 1. Industry Overview of Myasthenia Gravis Treatment Market
1.1. Definition and Scope
1.1.1. Definition of Myasthenia Gravis Treatment
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Myasthenia Gravis Treatment Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Myasthenia Gravis Treatment Market By Drug Class
1.2.3. Myasthenia Gravis Treatment Market By Distribution Channel
1.2.4. Myasthenia Gravis Treatment Market By Region
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Source
2.2.2. Primary Source
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restraint 1
3.2.2. Restraint 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Myasthenia Gravis Treatment Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Myasthenia Gravis Treatment Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Price Trend of Key Raw Material
3.8.1. Raw Material Suppliers
3.8.2. Proportion of Manufacturing Cost Structure
3.8.2.1. Raw Material
3.8.2.2. Labor Cost
3.8.2.3. Manufacturing Expense
3.9. Regulatory Compliance
3.10. Competitive Landscape, 2022
3.10.1. Player Positioning Analysis
3.10.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Manufacturing Plant Analysis
4.1. Manufacturing Plant Location and Establish Date of Major Manufacturers in 2022
4.2. R&D Status of Major Manufacturers in 2022
CHAPTER 5. Myasthenia Gravis Treatment Market By Drug Class
5.1. Introduction
5.2. Myasthenia Gravis Treatment Revenue By Drug Class
5.2.1. Myasthenia Gravis Treatment Revenue (USD Billion) and Forecast, By Drug Class, 2020-2032
5.2.2. Corticosteroids
5.2.2.1. Corticosteroids Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.3. IVIg
5.2.3.1. IVIg Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.4. Cholinesterase Inhibitors
5.2.4.1. Cholinesterase Inhibitors Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.5. Immunosuppressants
5.2.5.1. Immunosuppressants Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.6. Monoclonal Antibodies
5.2.6.1. Monoclonal Antibodies Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 6. Myasthenia Gravis Treatment Market By Distribution Channel
6.1. Introduction
6.2. Myasthenia Gravis Treatment Revenue By Distribution Channel
6.2.1. Myasthenia Gravis Treatment Revenue (USD Billion) and Forecast, By Distribution Channel, 2020-2032
6.2.2. Hospital Pharmacies
6.2.2.1. Hospital Pharmacies Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.3. Online Pharmacies
6.2.3.1. Online Pharmacies Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.4. Retail Pharmacies
6.2.4.1. Retail Pharmacies Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 7. North America Myasthenia Gravis Treatment Market By Country
7.1. North America Myasthenia Gravis Treatment Market Overview
7.2. U.S.
7.2.1. U.S. Myasthenia Gravis Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
7.2.2. U.S. Myasthenia Gravis Treatment Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
7.3. Canada
7.3.1. Canada Myasthenia Gravis Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
7.3.2. Canada Myasthenia Gravis Treatment Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
7.4. North America PEST Analysis
CHAPTER 8. Europe Myasthenia Gravis Treatment Market By Country
8.1. Europe Myasthenia Gravis Treatment Market Overview
8.2. U.K.
8.2.1. U.K. Myasthenia Gravis Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
8.2.2. U.K. Myasthenia Gravis Treatment Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
8.3. Germany
8.3.1. Germany Myasthenia Gravis Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
8.3.2. Germany Myasthenia Gravis Treatment Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
8.4. France
8.4.1. France Myasthenia Gravis Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
8.4.2. France Myasthenia Gravis Treatment Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
8.5. Spain
8.5.1. Spain Myasthenia Gravis Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
8.5.2. Spain Myasthenia Gravis Treatment Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
8.6. Rest of Europe
8.6.1. Rest of Europe Myasthenia Gravis Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
8.6.2. Rest of Europe Myasthenia Gravis Treatment Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
8.7. Europe PEST Analysis
CHAPTER 9. Asia Pacific Myasthenia Gravis Treatment Market By Country
9.1. Asia Pacific Myasthenia Gravis Treatment Market Overview
9.2. China
9.2.1. China Myasthenia Gravis Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
9.2.2. China Myasthenia Gravis Treatment Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
9.3. Japan
9.3.1. Japan Myasthenia Gravis Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
9.3.2. Japan Myasthenia Gravis Treatment Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
9.4. India
9.4.1. India Myasthenia Gravis Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
9.4.2. India Myasthenia Gravis Treatment Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
9.5. Australia
9.5.1. Australia Myasthenia Gravis Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
9.5.2. Australia Myasthenia Gravis Treatment Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
9.6. South Korea
9.6.1. South Korea Myasthenia Gravis Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
9.6.2. South Korea Myasthenia Gravis Treatment Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
9.7. Rest of Asia-Pacific
9.7.1. Rest of Asia-Pacific Myasthenia Gravis Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
9.7.2. Rest of Asia-Pacific Myasthenia Gravis Treatment Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
9.8. Asia Pacific PEST Analysis
CHAPTER 10. Latin America Myasthenia Gravis Treatment Market By Country
10.1. Latin America Myasthenia Gravis Treatment Market Overview
10.2. Brazil
10.2.1. Brazil Myasthenia Gravis Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
10.2.2. Brazil Myasthenia Gravis Treatment Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
10.3. Mexico
10.3.1. Mexico Myasthenia Gravis Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
10.3.2. Mexico Myasthenia Gravis Treatment Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
10.4. Rest of Latin America
10.4.1. Rest of Latin America Myasthenia Gravis Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
10.4.2. Rest of Latin America Myasthenia Gravis Treatment Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
10.5. Latin America PEST Analysis
CHAPTER 11. Middle East & Africa Myasthenia Gravis Treatment Market By Country
11.1. Middle East & Africa Myasthenia Gravis Treatment Market Overview
11.2. GCC
11.2.1. GCC Myasthenia Gravis Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
11.2.2. GCC Myasthenia Gravis Treatment Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
11.3. South Africa
11.3.1. South Africa Myasthenia Gravis Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
11.3.2. South Africa Myasthenia Gravis Treatment Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
11.4. Rest of Middle East & Africa
11.4.1. Rest of Middle East & Africa Myasthenia Gravis Treatment Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
11.4.2. Rest of Middle East & Africa Myasthenia Gravis Treatment Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
11.5. Middle East & Africa PEST Analysis
CHAPTER 12. Player Analysis Of Myasthenia Gravis Treatment Market
12.1. Myasthenia Gravis Treatment Market Company Share Analysis
12.2. Competition Matrix
12.2.1. Competitive Benchmarking Of Key Players By Price, Presence, Market Share, And R&D Investment
12.2.2. New Product Launches and Product Enhancements
12.2.3. Mergers And Acquisition In Global Myasthenia Gravis Treatment Market
12.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 13. Company Profile
13.1. Alexion Pharmaceuticals, Inc.
13.1.1. Company Snapshot
13.1.2. Business Overview
13.1.3. Financial Overview
13.1.3.1. Revenue (USD Billion), 2022
13.1.3.2. Alexion Pharmaceuticals, Inc. 2022 Myasthenia Gravis Treatment Business Regional Distribution
13.1.4. Product/Service and Specification
13.1.5. Recent Developments & Business Strategy
13.2. Grifols, S.A.
13.3. Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals)
13.4. Mylan N.V. (now part of Viatris Inc.)
13.5. Roche Holdings AG (including its subsidiary, Genentech)
13.6. Takeda Pharmaceutical Company Limited
13.7. Novartis AG
13.8. Pfizer Inc.
13.9. Bristol-Myers Squibb Company (now part of Bristol Myers Squibb)
13.10. Teva Pharmaceutical Industries Ltd.
13.11. AbbVie Inc.
13.12. Regeneron Pharmaceuticals, Inc.
Frequently Asked Questions
What was the market size of the global myasthenia gravis treatment in 2022?
The market size of myasthenia gravis treatment was USD 1.3 Billion in 2022.
What is the CAGR of the global myasthenia gravis treatment market from 2023 to 2032?
The CAGR of myasthenia gravis treatment is 7.3% during the analysis period of 2023 to 2032.
Which are the key players in the myasthenia gravis treatment market?
The key players operating in the global market are including Alexion Pharmaceuticals, Inc., Grifols, S.A., Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals), Mylan N.V. (now part of Viatris Inc.), Roche Holdings AG (including its subsidiary, Genentech), Takeda Pharmaceutical Company Limited, Novartis AG, Pfizer Inc., Bristol-Myers Squibb Company (now part of Bristol Myers Squibb), Teva Pharmaceutical Industries Ltd., AbbVie Inc., and Regeneron Pharmaceuticals, Inc.
Which region dominated the global myasthenia gravis treatment market share?
North America held the dominating position in myasthenia gravis treatment industry during the analysis period of 2023 to 2032.
Which region registered fastest CAGR from 2023 to 2032?
Asia-Pacific region exhibited fastest growing CAGR for market of myasthenia gravis treatment during the analysis period of 2023 to 2032.
What are the current trends and dynamics in the global myasthenia gravis treatment industry?
The current trends and dynamics in the myasthenia gravis treatment market growth include increasing prevalence of myasthenia gravis, advancements in treatment options and therapies, and rising awareness and early diagnosis.
Which drug class held the maximum share in 2022?
The IVIg drug class held the maximum share of the myasthenia gravis treatment industry.
Select Licence Type
Connect with our sales team
Why Acumen Research and Consulting
100%
Customer Satisfaction
24x7+
Availability - we are always there when you need us
200+
Fortune 50 Companies trust Acumen Research and Consulting
80%
of our reports are exclusive and first in the industry
100%
more data and analysis
1000+
reports published till date
